Human amyloid polypeptides (HIAPP), known as Amylin, is a 37-residual peptide hormone which is reported as a common factor in misinterpretation of protein folds such as type-2 diabetes mellitus, Alzheimer’s disease and Parkinson’s disease, due to unsoluble amyloid deposition of Hiapp on Pancreas and brain. Some studies show the importance of peptide interactions with biological membranes and cytotoxicity of hiap species. Here, we discuss the aggregation path of the fibril formation of Amyloid HIAPP and focus on complex interactions between HIAPP assembly mediated by membranes and mechanisms related to membrane damage caused by species of peptides.
The mitochondrial membrane, which is unique in their lipid composition, is proposed as the main target for the initial intracellular formation of toxic entities of Hiap. We suggest that future studies must include studies that are physiologically relevant and in cells to enable more accurate in vivo interaction models. Finally, we underline the urgent need to develop an effective therapeutic strategy aimed at blocking Hiap-phospholipid interactions.
Small nuclear ribonucleoprotein polypeptide n accelerates malignant development and poor prognosis in colorectal cancer is governed by E2F8
Colorectal cancer is the main cause of death throughout the world, and the identification of new diagnostic and prognostic biomarkers is very important to develop new strategies to avoid death-related collarectal cancer. Nuclear Small Ribonucleoprotein Polypeptide N (SNRPN) is a printed gene that plays an important role in a variety of neurodmental development disabilities. In this study, SNRPN was very expressed in colorectal cancer tissue and involved in the development of this disease. Immunohistochemical analysis of a sample of 1,310 colorectal cancer tissue shows that SNRPN is very stated in cancer tissue than on adjacent networks and is mainly localized in nucleus.
Analysis of clinical pathological factors showed that higher SNRPN expressions were significantly related to larger tumors, the location of the tumor on the large intestine left side, nerve invasion, and remote metastases. Univariate and multivariate analysis shows that SNRPN expression is an independent risk factor for survival, with a high level of expression that shows a worse overall survival. Both in vitro and in vivo experiments confirm that the high expression of SNRPN is associated with tumor proliferation, cell cycles, and metastasis.
Knowing the SNRPN blocked the cell cycle on the G2 / M phase transition and promoting tumor cell apoptosis, inhibiting the development of colorectal cancer. To explore the steam SNRPN, we found it with a luciferase reporter test and chromosome immunoprospitation test that E2F8 is a SNRPN vapor regulator in colorectal cancer. SNRPN systematic studies will help us find new regulatory molecules and provide theoretical basis for finding new molecular targets for this disease.
Citrus Fruit-Derivative Flavanone Glycoside Narirutin is a strong novel inhibitor of the organic annealing polypeptide
Polypeptide Transportation of Organic Anion (OATP) 1A2 and OATP2B1 is expressed in the small intestine and is involved in drug absorption. We identify narirutin, which is present in Balinese orange juice, as a new OATP inhibitor. Jabara orange fruit also contains high level narifies; Therefore, we investigate the potential for inhibition of Jaba Juice against wheat. The inhibition effect of various related compounds in wheat transportation activities is evaluated using HEK293 cells that express OATP.
The value of IC50 narirutin for transportation mediated by OATP1A2- and OATP2B1 are 22.6 and 18.2 μm respectively. Other flavanone derivatives from grapefruit juice also inhibit transportation mediated OATP1A2 / OATP2B1 (sequence of potential inhibition: narryenin> narirutin> naringin). Jabara Juice five percent significantly inhibits transportation mediated OATP1A2- and OATP2B1 of 67 ± 11 and 81 ± 5.5%, respectively (p <0.05). Based on their potential and inhibitory levels in grapefruit juice, wheat inhibition with bali orange juice caused by naringin and narirutin. Citrus × Jabara, which contains narirutin, potential inhibits transportation mediated by OATP.
Insight into the functions of Jaburetox and Soyuretox: novels intrinsically polypeptides that the disorderized originates from plants
Intrinsically irregular proteins (IDP) and irregular intrinsic areas (IDRs) do not have a stable 3D structure but still have important biological activities. Jaburetox is a recombinant peptide that comes from Urease Jack Bean (Canavalia Iensifics) and presents entomotoxic and antimicrobial actions. The Jaburetox structure is explained by using nuclear magnetic resonance which reveals it is IDP with a small number of secondary structures. Different approaches have shown that Jaburetox acquires certain folds on interactions with lipid membranes, characteristics commonly found in other refugees and are usually important for their biological functions.
Soyuretox, recombinant peptides originating from fatigue (glycine max) urease and homologous on Jaburetox, are also marked for biological activities and structural properties. Soyuretox is also an IDP, presents more secondary structures compared to Jaburetox and similar entomotoxic and fungitoxic effects. In addition, Soyuretox was found to be non-toxic to zebras, while Jaburetox was not harmful to mice and mice.
NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
| 047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
| 047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
| 047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
FGL Peptide - FAM Labeled |
|||
| FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
FGL Peptide - Cy3 Labeled |
|||
| FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
FGL Peptide - Cy5 Labeled |
|||
| FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
Pedal Peptide (Pep) (Aplysia) |
|||
| 047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
ExE peptide M3mP6 mutant |
|||
| 064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
| 064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
FGL Peptide - FITC Labeled |
|||
| FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
AF-16 Peptide - Antibody |
|||
| H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
Schizophrenia Related Peptide |
|||
| 047-79 | PHOENIX PEPTIDE | 5 mg | EUR 44.28 |
Insulin B (22-25) Peptide |
|||
| 035-08 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
Eosinophilotactic Peptide (AGSE) |
|||
| 070-28 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Eosinophilotactic Peptide (VGSE) |
|||
| 070-29 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Cell Penetrating ARF Peptide (26-44) |
|||
| 068-56 | PHOENIX PEPTIDE | 500 μg | EUR 640.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
| RK-064-01 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
FGL Peptide - Biotin Labeled |
|||
| B-073-36 | PHOENIX PEPTIDE | 20 μg | EUR 405 |
Peptide F (Bovine) - Antibody |
|||
| H-024-58 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Brain Peptide (Bees) Library |
|||
| L-007 | PHOENIX PEPTIDE | 51 peptides | EUR 6456.24 |
Gastrointestinal Peptide Library |
|||
| L-006 | PHOENIX PEPTIDE | 200 peptides | EUR 7267.32 |
Peptide R / CXCR4 Antagonist |
|||
| 030-25 | PHOENIX PEPTIDE | 200 μg | EUR 203.04 |
PGMtide Peptide - FAM Labeled |
|||
| FG-040-69A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
PGMtide Peptide - Cy3 Labeled |
|||
| FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
| 033-34 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
| H-064-07 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
[D-Ala1]-Peptide T amide |
|||
| 057-03 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
Peptide F (Bovine) - RIA Kit |
|||
| RK-024-58 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Calmodulin Binding Peptide 1 |
|||
| 070-17 | PHOENIX PEPTIDE | 20 μg | EUR 214.92 |
Catch-Relaxing Peptide (CARP) |
|||
| 047-20 | PHOENIX PEPTIDE | 1 mg | EUR 199.8 |
FGL Peptide - Rhodamine Labeled |
|||
| FR-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 537.84 |
Peptide-Depleted Plasma (Rat) |
|||
| MB-099-02 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
| RK-064-07 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Glycogenolysis-Inhibiting Peptide |
|||
| 023-63 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Anti-Inflammatory Peptide 1 |
|||
| 004-01 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 2 |
|||
| 004-02 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 3 |
|||
| 004-03 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Urokinase-Derived Peptide A6 |
|||
| 025-12 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide - Biotin Labeled |
|||
| B-040-69 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
Peptide 34 / GPR-54 Agonist |
|||
| 048-94 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
FGL Peptide - I-125 Labeled |
|||
| T-073-36 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Peptide-Depleted Plasma (Human) |
|||
| MB-099-01 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
| FG-064-07A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
| T-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
F3 Peptide / HMGN2 Fragment 3 |
|||
| 004-12 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Antimicrobial Trp-rich peptide |
|||
| 004-05 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Myosin Kinase Inhibiting Peptide |
|||
| 058-20 | PHOENIX PEPTIDE | 500 μg | EUR 50.76 |
Fibronectin CS1 Peptide (EILDVPST) |
|||
| 025-20 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Peptide YY (PYY) (3-36) (Human) |
|||
| 059-02 | PHOENIX PEPTIDE | 200 μg | EUR 102.6 |
Peptide YY (PYY) (Human) - Antibody |
|||
| H-059-01 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
PGMtide Peptide - Rhodamine Labeled |
|||
| FR-040-69 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
Anti-Angiogenic Peptide Library |
|||
| L-008A | PHOENIX PEPTIDE | 88 peptides | EUR 6067.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
| G-064-01 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Peptide A / p60v-src (137-157) |
|||
| 058-21 | PHOENIX PEPTIDE | 500 μg | EUR 135 |
pro-Opionmelanocortin / J Peptide |
|||
| 022-22 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Cancer-Targeting Peptide Library |
|||
| L-015 | PHOENIX PEPTIDE | 289 peptides | EUR 7253.28 |
C28 optimized peptide 6 (Human) |
|||
| 073-82 | PHOENIX PEPTIDE | 100 μg | EUR 235.44 |
Peptide YY (PYY) (Human) - EIA Kit |
|||
| EK-059-01 | PHOENIX PEPTIDE | 96 wells | EUR 617.76 |
Peptide YY (PYY) (Human) - RIA Kit |
|||
| RK-059-01 | PHOENIX PEPTIDE | 125 tubes | EUR 814.32 |
Kemptide / Phosphate Acceptor Peptide |
|||
| 058-16 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Bioactive Secretory Peptide Library |
|||
| L-009 | PHOENIX PEPTIDE | 1016 peptides | EUR 31350.24 |
PACAP-Related Peptide (PRP) (Rat) |
|||
| 052-11 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Galanin-Like Peptide (GALP) (Rat) |
|||
| 026-52 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
DISP3 Peptide |
|||
| 4893P | ProSci | 0.05 mg | EUR 197.7 |
|
Description: (NT) DISP2 peptide |
|||
DISP1 Peptide |
|||
| 6629P | ProSci | 0.05 mg | EUR 197.7 |
|
Description: (NT) DISP1 peptide |
|||
DISP3 Peptide |
|||
| MBS153195-005mg | MyBiosource | 0.05mg | EUR 175 |
DISP3 Peptide |
|||
| MBS153195-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
DISP1 Peptide |
|||
| MBS153278-005mg | MyBiosource | 0.05mg | EUR 175 |
DISP1 Peptide |
|||
| MBS153278-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled |
|||
| T-064-07 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Virus Replication Inhibiting Peptide |
|||
| 070-85 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
Crustacean Cardioactive Peptide (CCAP) |
|||
| 047-24 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Pri Peptide from sORF pri RNA |
|||
| 069-77 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Alzheimer Fingerprint Peptide Library |
|||
| L-011 | PHOENIX PEPTIDE | 85 peptides | EUR 6529.68 |
u PAR (84-95) Scrambled Peptide |
|||
| 072-47 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
PACAP-Related Peptide (PRP) (Human) |
|||
| 052-10 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Scrambled Control for Pri Peptide |
|||
| 069-78 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
FMRF-Like Peptide (Helix aspersa) |
|||
| 047-31 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Annexin A1 Binding Peptide, IF7CRR |
|||
| 025-72 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Galanin-Like Peptide (GALP) (Human) |
|||
| 026-51 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Rat) |
|||
| 027-32 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
Kinetensin / Neurotensin Related Peptide |
|||
| 048-01 | PHOENIX PEPTIDE | 500 μg | EUR 58.32 |
Small Cardioactive Peptide A (SCPA) |
|||
| 047-76 | PHOENIX PEPTIDE | 1 mg | EUR 64.8 |
Gastrin Releasing Peptide (GRP) (Frog) |
|||
| 027-33 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
Epidermal Growth Factor Receptor Peptide (985-996) |
|||
| 030-05 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody |
|||
| G-064-07 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Galanin-Like Peptide (GALP) (Porcine) |
|||
| 026-50 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Human) |
|||
| 027-07 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Gastrin Releasing Peptide (GRP) (Mouse) |
|||
| 027-40 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
PGMtide Control Peptide - FAM Labeled |
|||
| FG-040-70A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
Growth Blocking Peptide - FAM Labeled |
|||
| FG-046-92A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
PGMtide Control Peptide - Cy3 Labeled |
|||
| FC3-040-70 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
Chop-Suey / Variety Peptide Library |
|||
| L-001 | PHOENIX PEPTIDE | 238 peptides | EUR 7400.16 |
T3 Peptide / Tumstatin (69-88) (Human) |
|||
| 016-50 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
T7 Peptide / Tumstatin (74-98) (Human) |
|||
| 016-51 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Peptide YY (PYY) (1-36)-Gly (Human) |
|||
| 059-07 | PHOENIX PEPTIDE | 100 μg | EUR 295.92 |
Peptide YY (PYY) (3-36)-Gly (Human) |
|||
| 059-08 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
Peptide YY (PYY) (2-36)-Gly (Human) |
|||
| 059-11 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Peptide YY (PYY) (4-36)-Gly (Human) |
|||
| 059-12 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
This toxicity profile affects adverse species without damaging mammals or environmentally qualified for use in biotechnology applications. Both peptides are employed to develop transgenic plants and these plants actively fight insects and nematodes, uncover their great potential for field applications.
